Search
Protalix Biotherapeutics Inc
PLXAdd to Watchlist
2.320USD
+0.015+0.65%
Close 07/02, 13:00（ET）Quotes delayed by 15 min
143.85MMarket Cap
12.01P/E TTM
More Details of Protalix Biotherapeutics Inc Company
Protalix BioTherapeutics, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of recombinant therapeutic proteins expressed through its proprietary plant cell-based expression system, ProCellEx. In addition, the Company is developing PEGylated uricase, or PRX-115, for the treatment of uncontrolled gout, Long Acting (LA) DNase I, or PRX-119, for the treatment of NETs-related diseases, and other technologies and preclinical assets. Its ProCellEx platform is being used to manufacture both of its approved and marketed products as well as PRX-115 and PRX-119. PRX-115, a plant cell-expressed recombinant PEGylated Uricase (urate oxidase) - a chemically modified enzyme to treat uncontrolled gout. PRX-119 is a plant cell-expressed PEGylated recombinant human DNase I product candidate. Its product includes Elelyso and Elfabrio. Elelyso is an enzyme replacement therapy (ERT) for the treatment of patients with Gaucher disease.
Protalix Biotherapeutics Inc Info
Ticker SymbolPLX
Company nameProtalix Biotherapeutics Inc
IPO dateSep 06, 2010
CEOBashan (Dror)
Number of employees207
Security typeOrdinary Share
Fiscal year-endSep 06
Address2 University Plaza
CityHACKENSACK
Stock exchangeNASDAQ OMX – NASDAQ Basic Amex
CountryUnited States of America
Postal code07601
Phone12016969345
Websitehttps://protalix.com/
Ticker SymbolPLX
IPO dateSep 06, 2010
CEOBashan (Dror)
Company Executives of Protalix Biotherapeutics Inc
Name
Name/Position
Position
Shareholding
Change
Mr. Dror Bashan
Mr. Dror Bashan
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
2.53M
+7.70%
Dr. Aharon Schwartz, Ph.D.
Dr. Aharon Schwartz, Ph.D.
Independent Director
Independent Director
310.50K
+2.42%
Mr. Yaron Naos
Mr. Yaron Naos
Senior Vice President - Operations
Senior Vice President - Operations
232.30K
+10.76%
Dr. Pol F. Boudes, M.D.
Dr. Pol F. Boudes, M.D.
Independent Director
Independent Director
7.54K
+99.47%
Ms. Gwen A. Melincoff
Ms. Gwen A. Melincoff
Independent Director
Independent Director
7.50K
+99.47%
Mr. Gilad Mamlok
Mr. Gilad Mamlok
Chief Financial Officer, Senior Vice President
Chief Financial Officer, Senior Vice President
3.63K
--
Mr. Amos Bar Shalev
Mr. Amos Bar Shalev
Independent Director
Independent Director
--
--
Dr. Shmuel (Muli) Ben-Zvi, Ph.D.
Dr. Shmuel (Muli) Ben-Zvi, Ph.D.
Independent Director
Independent Director
--
--
Dr. Eliot Richard Forster, Ph.D.
Dr. Eliot Richard Forster, Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Mr. Mike Moyer
Mr. Mike Moyer
Investor Relations
Investor Relations
--
--
Name
Name/Position
Position
Shareholding
Change
Mr. Dror Bashan
Mr. Dror Bashan
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
2.53M
+7.70%
Dr. Aharon Schwartz, Ph.D.
Dr. Aharon Schwartz, Ph.D.
Independent Director
Independent Director
310.50K
+2.42%
Mr. Yaron Naos
Mr. Yaron Naos
Senior Vice President - Operations
Senior Vice President - Operations
232.30K
+10.76%
Dr. Pol F. Boudes, M.D.
Dr. Pol F. Boudes, M.D.
Independent Director
Independent Director
7.54K
+99.47%
Ms. Gwen A. Melincoff
Ms. Gwen A. Melincoff
Independent Director
Independent Director
7.50K
+99.47%
Mr. Gilad Mamlok
Mr. Gilad Mamlok
Chief Financial Officer, Senior Vice President
Chief Financial Officer, Senior Vice President
3.63K
--
FAQs
Who are the top five shareholders of Protalix Biotherapeutics Inc?
The top five shareholders of Protalix Biotherapeutics Inc are: Mr. Dror Bashan
How many institutions hold shares of Protalix Biotherapeutics Inc (PLX)?
As of 2026Q1, 193 institutions hold shares of Protalix Biotherapeutics Inc, with a combined market value of approximately 19.91M, accounting for 24.71% of the total shares. Compared to 2025Q4, institutional shareholding has increased by 2149424.00.